Glenmark Pharmaceuticals launches rufinamide tablets
MUMBAI, India – Glenmark Pharmaceuticals (Glenmark) has launched rufinamide tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for rufinamide tablets USP, 200 mg and 400 mg, with a paragraph
